Identification

Name
Metformin
Accession Number
DB00331  (APRD01099)
Type
Small Molecule
Groups
Approved
Description

Metformin is a biguanide antihyperglycemic agent used for treating non-insulin-dependent diabetes mellitus (NIDDM). It improves glycemic control by decreasing hepatic glucose production, decreasing glucose absorption and increasing insulin-mediated glucose uptake. Metformin may induce weight loss and is the drug of choice for obese NIDDM patients. Use of metformin is associated with modest weight loss. When used alone, metformin does not cause hypoglycemia; however, it may potentiate the hypoglycemic effects of sulfonylureas and insulin. Its main side effects are dyspepsia, nausea and diarrhea. Dose titration and/or use of smaller divided doses may decrease side effects. Metformin should be avoided in those with severely compromised renal function (creatinine clearance < 30 ml/min), acute/decompensated heart failure, severe liver disease and for 48 hours after the use of iodinated contrast dyes due to the risk of lactic acidosis. Lower doses should be used in the elderly and those with decreased renal function. Metformin decreases fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Metformin may also have a positive effect on lipid levels. In 2012, a combination tablet of linagliptin plus metformin hydrochloride was marketed under the name Jentadueto for use in patients when treatment with both linagliptin and metformin is appropriate.

Structure
Thumb
Synonyms
  • 1,1-Dimethylbiguanide
  • Dimethylbiguanid
  • Metformin
  • Metformina
  • Metformine
  • Metforminum
External IDs
LA 6023
Product Ingredients
IngredientUNIICASInChI Key
Metformin Hydrochloride786Z46389E1115-70-4OETHQSJEHLVLGH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act MetforminTablet500 mgOralActavis Pharma Company2004-11-05Not applicableCanada
Act MetforminTablet850 mgOralActavis Pharma Company2004-11-05Not applicableCanada
Auro-metforminTablet500 mgOralAuro Pharma Inc2015-04-08Not applicableCanada
Auro-metforminTablet850 mgOralAuro Pharma Inc2015-04-08Not applicableCanada
Ava-metforminTablet500 mgOralAvanstra Inc2011-09-152014-08-21Canada
Ava-metforminTablet850 mgOralAvanstra Inc2011-09-152014-08-21Canada
Bci MetforminTablet500 mgOralBaker Cummins Inc2005-04-072006-10-03Canada
Bci MetforminTablet850 mgOralBaker Cummins Inc2005-07-042006-10-03Canada
Bio-metforminTablet500 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-metforminTablet850 mgOralBiomed PharmaNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-metformin - Tab 500mgTablet500 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-metformin 850 Mg TabletsTablet850 mgOralApotex Corporation1996-11-20Not applicableCanada
Apo-metformin ERTablet, extended release500 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-metformin ERTablet, extended release1000 mgOralApotex CorporationNot applicableNot applicableCanada
Dm2KitHudson Scientific Llc2017-01-20Not applicableUs
Dm2KitHudson Scientific Llc2017-06-16Not applicableUs
Metfomin HydrochlorideTablet850 mg/1OralRemedy Repack2011-08-102016-11-04Us
Metformin HClTablet, film coated500 mg/1OralTime Cap Laboratories2016-11-14Not applicableUs
Metformin HClTablet850 mg/1OralAscend Laboratories, LLC2017-02-06Not applicableUs
Metformin HClTablet, film coated1000 mg/1OralTime Cap Laboratories2016-11-14Not applicableUs
International/Other Brands
Apo-Metformin (Apotex) / Gen-Metformin (Genpharm ULC) / Novo-Metformin (Novopharm) / Nu-Metformin (Nu-Pharm) / Sandoz Metformin (Sandox)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Actoplus MetMetformin Hydrochloride (850 mg/1) + Pioglitazone Hydrochloride (15 mg/1)Tablet, film coatedOralTakeda2005-08-29Not applicableUs
Actoplus MetMetformin Hydrochloride (500 mg/1) + Pioglitazone Hydrochloride (15 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2006-01-04Not applicableUs
Actoplus MetMetformin Hydrochloride (850 mg/1) + Pioglitazone Hydrochloride (15 mg/1)Tablet, film coatedOralCardinal Health2005-08-29Not applicableUs
Actoplus MetMetformin Hydrochloride (850 mg/1) + Pioglitazone Hydrochloride (15 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2006-03-21Not applicableUs
Actoplus MetMetformin Hydrochloride (500 mg/1) + Pioglitazone Hydrochloride (15 mg/1)Tablet, film coatedOralTakeda2005-08-29Not applicableUs
Actoplus Met XRMetformin Hydrochloride (1000 mg/1) + Pioglitazone Hydrochloride (30 mg/1)Tablet, film coated, extended releaseOralTakeda2010-06-11Not applicableUs
Actoplus Met XRMetformin Hydrochloride (1000 mg/1) + Pioglitazone Hydrochloride (15 mg/1)Tablet, film coated, extended releaseOralTakeda2010-06-11Not applicableUs
Alogliptin and Metformin HydrochlorideMetformin Hydrochloride (500 mg/1) + Alogliptin Benzoate (12.5 mg/1)Tablet, film coatedOralPerrigo New York Inc.2016-04-08Not applicableUs
Alogliptin and Metformin HydrochlorideMetformin Hydrochloride (1000 mg/1) + Alogliptin Benzoate (12.5 mg/1)Tablet, film coatedOralPerrigo New York Inc.2016-04-08Not applicableUs
AppforminMetformin Hydrochloride + L-TyrosineKitPhysician Therapeutics Llc2011-02-072016-10-13Us
Categories
UNII
9100L32L2N
CAS number
657-24-9
Weight
Average: 129.1636
Monoisotopic: 129.101445377
Chemical Formula
C4H11N5
InChI Key
XZWYZXLIPXDOLR-UHFFFAOYSA-N
InChI
InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
IUPAC Name
1-carbamimidamido-N,N-dimethylmethanimidamide
SMILES
CN(C)C(=N)NC(N)=N

Pharmacology

Indication

For use as an adjunct to diet and exercise in adult patients (18 years and older) with NIDDM. May also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome (PCOS). Jentadueto is for the treatment of patients when both linagliptin and metformin is appropriate.

Structured Indications
Pharmacodynamics

Metformin is an oral antihyperglycemic agent that improves glucose tolerance in patients with NIDDM, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other class of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with NIDDM or healthy subjects and does not cause hyperinsulinemia. Metformin does not affect insulin secretion.

Mechanism of action

Metformin's mechanisms of action differ from other classes of oral antihyperglycemic agents. Metformin decreases blood glucose levels by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. These effects are mediated by the initial activation by metformin of AMP-activated protein kinase (AMPK), a liver enzyme that plays an important role in insulin signaling, whole body energy balance, and the metabolism of glucose and fats. Activation of AMPK is required for metformin's inhibitory effect on the production of glucose by liver cells. Increased peripheral utilization of glucose may be due to improved insulin binding to insulin receptors. Metformin administration also increases AMPK activity in skeletal muscle. AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake. The rare side effect, lactic acidosis, is thought to be caused by decreased liver uptake of serum lactate, one of the substrates of gluconeogenesis. In those with healthy renal function, the slight excess is simply cleared. However, those with severe renal impairment may accumulate clinically significant serum lactic acid levels. Other conditions that may precipitate lactic acidosis include severe hepatic disease and acute/decompensated heart failure.

TargetActionsOrganism
A5'-AMP-activated protein kinase subunit beta-1
inducer
Human
Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Administration with food decreases and delays absorption. Some evidence indicates that the level of absorption is not dose-related, suggesting that absorption occurs through a saturable process. Limited data from animal and human cell cultures indicate that absorption occurs through a passive, non-saturable process, possibly involving a paracellular route. Peak action occurs 3 hours after oral administration.

Volume of distribution

654 L for metformin 850 mg administered as a single dose. The volume of distribution following IV administration is 63-276 L, likely due to less binding in the GI tract and/or different methods used to determine volume of distribution.

Protein binding

Metformin is negligibly bound to plasma proteins.

Metabolism

Metformin is not metabolized.

Route of elimination

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Approximately 90% of the drug is eliminated in 24 hours in those with healthy renal function. Renal clearance of metformin is approximately 3.5 times that of creatinine clearance, indicating the tubular secretion is the primary mode of metformin elimination.

Half life

6.2 hours. Duration of action is 8-12 hours.

Clearance

718-1552 mL/minute following single oral dose of 0.5-1.5 g. Metformin is removed by hemodialysis at a rate of approximately 170 ml/min under good hemodynamic conditions.

Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Metformin.Experimental
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Metformin.Approved, Vet Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Metformin.Experimental
AloxiprinAloxiprin may increase the hypoglycemic activities of Metformin.Experimental
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Metformin.Approved
AripiprazoleThe therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Metformin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.Approved, Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Metformin.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Metformin.Withdrawn
BetamethasoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BrexpiprazoleThe therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Brinzolamide is combined with Metformin.Approved
BrofaromineBrofaromine may increase the hypoglycemic activities of Metformin.Experimental
BumetanideThe therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.Approved
BupropionThe serum concentration of Metformin can be increased when it is combined with Bupropion.Approved
BuserelinThe therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Metformin.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Metformin.Withdrawn
CephalexinThe serum concentration of Metformin can be increased when it is combined with Cephalexin.Approved, Vet Approved
CeritinibThe therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideMetformin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.Approved
CimetidineThe serum concentration of Metformin can be increased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Metformin.Approved, Withdrawn
CitalopramCitalopram may increase the hypoglycemic activities of Metformin.Approved
ClozapineThe therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate.Approved
CyclopenthiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.Approved
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Metformin.Approved
DanazolThe therapeutic efficacy of Metformin can be decreased when used in combination with Danazol.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Metformin.Investigational
DarunavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Metformin.Investigational
DesogestrelThe therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Metformin.Approved
DexamethasoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiatrizoateThe risk or severity of adverse effects can be increased when Diatrizoate is combined with Metformin.Approved, Vet Approved
DiazoxideThe therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin.Approved
DienogestThe therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Metformin.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Metformin.Illicit
DisopyramideMetformin may increase the hypoglycemic activities of Disopyramide.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Metformin.Approved
DolutegravirThe serum concentration of Metformin can be increased when it is combined with Dolutegravir.Approved
DorzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Metformin.Approved
DrospirenoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Metformin.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Metformin.Approved
EpinephrineThe therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Metformin.Approved, Investigational
EstradiolThe therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Metformin.Approved
Ethinyl EstradiolThe therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethiodized oilThe risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Metformin.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Metformin.Approved
EverolimusThe therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Metformin.Approved
FludrocortisoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Metformin.Withdrawn
FluoxetineFluoxetine may increase the hypoglycemic activities of Metformin.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Metformin.Approved, Illicit
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Metformin.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Fosamprenavir.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Metformin.Approved, Vet Approved
FurosemideThe therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Metformin.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Metformin.Approved, Investigational
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Metformin.Approved, Investigational
GliclazideMetformin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMetformin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMetformin may increase the hypoglycemic activities of Glipizide.Approved
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Metformin.Investigational
GlyburideMetformin may increase the hypoglycemic activities of Glyburide.Approved
GlycopyrroniumThe serum concentration of Metformin can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GoserelinThe therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Metformin.Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Metformin.Experimental
HarmalineHarmaline may increase the hypoglycemic activities of Metformin.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Metformin.Experimental
HistrelinThe therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Metformin.Experimental
HydrochlorothiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Metformin.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir.Approved
Insulin AspartMetformin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMetformin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMetformin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMetformin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMetformin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMetformin may increase the hypoglycemic activities of Insulin Lispro.Approved
IodipamideThe risk or severity of adverse effects can be increased when Iodipamide is combined with Metformin.Approved
IodixanolThe risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin.Approved
IohexolThe risk or severity of adverse effects can be increased when Iohexol is combined with Metformin.Approved
IopamidolThe risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.Approved
IopromideThe risk or severity of adverse effects can be increased when Iopromide is combined with Metformin.Approved
IoversolThe risk or severity of adverse effects can be increased when Ioversol is combined with Metformin.Approved
IoxilanThe risk or severity of adverse effects can be increased when Ioxilan is combined with Metformin.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Metformin.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Metformin.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Metformin.Approved
LamotrigineThe serum concentration of Metformin can be increased when it is combined with Lamotrigine.Approved, Investigational
LanreotideThe therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Metformin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Metformin.Approved
LevonorgestrelThe therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Metformin.Approved, Nutraceutical
LopinavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Metformin.Withdrawn
MecaserminMetformin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Metformin.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Metformin.Experimental
MestranolThe therapeutic efficacy of Metformin can be decreased when used in combination with Mestranol.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Metformin.Approved
MethotrimeprazineThe therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Metformin.Investigational
MethylprednisoloneThe therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Metformin.Approved
MetolazoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.Approved
MifepristoneMetformin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Metformin.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Metformin.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Metformin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Metformin.Approved
NandroloneNandrolone may increase the hypoglycemic activities of Metformin.Experimental
NateglinideMetformin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Metformin.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Metformin.Investigational
NiacinThe therapeutic efficacy of Metformin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Metformin.Withdrawn
NilotinibThe therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Metformin.Investigational
NorethisteroneThe therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Metformin.Approved
NorgestimateThe therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Metformin.Withdrawn
OctreotideThe therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Metformin.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Metformin.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Metformin.Experimental
OxymetholoneOxymetholone may increase the hypoglycemic activities of Metformin.Approved, Illicit
PaliperidoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.Approved
PargylinePargyline may increase the hypoglycemic activities of Metformin.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Metformin.Approved, Investigational
PasireotideThe therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Metformin.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Metformin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Metformin.Approved
PentamidineThe therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Metformin.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Metformin.Withdrawn
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Metformin.Withdrawn
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Metformin.Experimental
PiperazineThe therapeutic efficacy of Metformin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Metformin.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Metformin.Experimental
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Metformin.Withdrawn
PolythiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide.Approved
PrednisoloneThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Metformin.Investigational
QuetiapineThe therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone.Approved
QuinineMetformin may increase the hypoglycemic activities of Quinine.Approved
RanolazineThe serum concentration of Metformin can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Metformin.Approved
RepaglinideMetformin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RisperidoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Metformin.Approved
RufloxacinRufloxacin may increase the hypoglycemic activities of Metformin.Experimental
SafrazineSafrazine may increase the hypoglycemic activities of Metformin.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Metformin.Approved, Vet Approved
SaquinavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.Approved, Investigational
SelegilineSelegiline may increase the hypoglycemic activities of Metformin.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Metformin.Approved
SirolimusThe therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Metformin.Experimental
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Metformin.Approved
StanozololStanozolol may increase the hypoglycemic activities of Metformin.Approved, Vet Approved
SulfadiazineMetformin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleMetformin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleMetformin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibMetformin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Metformin.Withdrawn
TemsirolimusThe therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Metformin.Approved, Investigational
TipranavirThe therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideMetformin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideMetformin may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Metformin.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Metformin.Approved
TorasemideThe therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Metformin.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Metformin.Approved
TriamcinoloneThe therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethoprimThe serum concentration of Metformin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TrospiumThe serum concentration of Trospium can be decreased when it is combined with Metformin.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Metformin.Approved, Withdrawn
VandetanibThe serum concentration of Metformin can be increased when it is combined with Vandetanib.Approved
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Metformin.Approved
VerapamilThe therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.Approved
VorinostatThe therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Metformin.Withdrawn
ZiprasidoneThe therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Jorn Moeckel, Rolf-Dieter Gabel, Heinrich Woog, "Pharmaceutical preparation containing metformin and a process for producing it." U.S. Patent US5955106, issued October, 1991.

US5955106
General References
  1. Witters LA: The blooming of the French lilac. J Clin Invest. 2001 Oct;108(8):1105-7. [PubMed:11602616]
  2. UNGAR G, FREEDMAN L, SHAPIRO SL: Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med. 1957 May;95(1):190-2. [PubMed:13432032]
  3. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003 Oct 25;327(7421):951-3. [PubMed:14576245]
  4. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet. 2001 Sep 15;358(9285):893-4. [PubMed:11567710]
  5. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP: Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8. [PubMed:15225167]
External Links
Human Metabolome Database
HMDB01921
KEGG Drug
D04966
KEGG Compound
C07151
PubChem Compound
4091
PubChem Substance
46507752
ChemSpider
3949
BindingDB
50229665
ChEBI
6801
ChEMBL
CHEMBL1431
Therapeutic Targets Database
DAP000205
PharmGKB
PA450395
HET
MF8
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Metformin
ATC Codes
A10BD18 — Metformin and gemigliptinA10BA02 — MetforminA10BD13 — Metformin and alogliptinA10BD03 — Metformin and rosiglitazoneA10BD10 — Metformin and saxagliptinA10BD16 — Metformin and canagliflozinA10BD02 — Metformin and sulfonylureasA10BD14 — Metformin and repaglinideA10BD15 — Metformin and dapagliflozinA10BD05 — Metformin and pioglitazoneA10BD08 — Metformin and vildagliptinA10BD20 — Metformin and empagliflozinA10BD11 — Metformin and linagliptinA10BD07 — Metformin and sitagliptinA10BD17 — Metformin and acarbose
AHFS Codes
  • 68:20.04 — Biguanides
PDB Entries
5g5j
FDA label
Download (239 KB)
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentEndometrial Hyperplasia / Endometrial Hyperplasia Without Atypia1
0CompletedBasic ScienceCardiovascular Disease (CVD)1
0CompletedBasic ScienceHead and Neck Squamous Cell Cancer1
0CompletedPreventionLong Segment Barrett's Esophagus / Short Segment Barrett's Esophagus1
0CompletedPreventionPolycystic Ovaries Syndrome1
0CompletedTreatmentDiet Tolerability / Fasting Glucose / Metformin Concentration / Metformin Response / Tryptophan Concentration1
0CompletedTreatmentEndometrial Cancers2
0CompletedTreatmentPolycystic Ovaries Syndrome1
0Not Yet RecruitingOtherGlioblastomas1
0Not Yet RecruitingPreventionAtrophy, Disuse / Insulin Resistance1
0RecruitingPreventionRetinopathy, Diabetic1
0RecruitingSupportive CareLarynx / LIP / Oral Cavity / Pharynx1
0RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage I-III Pancreatic Cancer1
0RecruitingTreatmentCancer of Breast / Cancer, Breast / Tumors, Breast1
0RecruitingTreatmentHemoglobin Disease; Sickle-Cell, Thalassemia / Hemoglobin Disorder / Sickle Cell Disorders1
0RecruitingTreatmentNeuroendocrine Tumors1
0RecruitingTreatmentPolycystic Ovarian Syndrome1
0TerminatedBasic ScienceCancer of Head and Neck1
0Unknown StatusTreatmentPolycystic Ovarian Syndrome1
1Active Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentBrain Cancer1
1Active Not RecruitingTreatmentDiabetes Insipidus1
1Active Not RecruitingTreatmentHealthy Volunteers1
1Active Not RecruitingTreatmentNeoplasms, Breast / Stage 0 Breast Carcinoma / Stage I Breast Carcinoma / Stage II Breast Carcinoma / Stage III Breast Carcinoma1
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
1CompletedNot AvailableBMI >30 kg/m21
1CompletedNot AvailableChronic Hepatitis C Infection / Diabetes Mellitus (DM) / Insulin Resistance1
1CompletedNot AvailableDepressive State / Type 2 Diabetes Mellitus1
1CompletedNot AvailableDiabetes1
1CompletedNot AvailableDiabetes Mellitus (DM)2
1CompletedNot AvailableDiabetes / Healthy Male and Female Subjects1
1CompletedNot AvailableHealthy Male Volunteers1
1CompletedNot AvailableHealthy Volunteers29
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Metformin1
1CompletedNot AvailableType 2 Diabetes Mellitus14
1CompletedBasic ScienceHealthy Volunteers12
1CompletedBasic ScienceInsulin Resistance / Prediabetic State1
1CompletedBasic SciencePre-Diabetic1
1CompletedBasic ScienceType 2 Diabetes Mellitus3
1CompletedDiagnosticHealthy Volunteers1
1CompletedDiagnosticHealthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedOtherHealthy Volunteers2
1CompletedPreventionDiabetes1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentBioequivalence1
1CompletedTreatmentCancer, Breast2
1CompletedTreatmentCancer, Breast / Endometrial Cancers / Lung Cancers / Malignant Lymphomas / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancers1
1CompletedTreatmentDiabetes / Healthy Volunteers2
1CompletedTreatmentDiabetes / Healthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedTreatmentDiabetes / Hyperlipidemias1
1CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus2
1CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
1CompletedTreatmentHealthy Elderly1
1CompletedTreatmentHealthy Participants1
1CompletedTreatmentHealthy Volunteers46
1CompletedTreatmentLi-Fraumeni Syndrome1
1CompletedTreatmentPain, Neuropathic1
1CompletedTreatmentType 2 Diabetes Mellitus21
1CompletedTreatmentType2 Diabetes Mellitus1
1Enrolling by InvitationTreatmentHealthy Volunteers1
1Not Yet RecruitingOtherHealthy Volunteers1
1Not Yet RecruitingTreatmentCancer, Advanced / Tumors, Solid1
1Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
1RecruitingBasic ScienceAging1
1RecruitingBasic ScienceNon-Alcoholic Fatty Liver Disease (NAFLD)1
1RecruitingBasic ScienceType 2 Diabetes Mellitus1
1RecruitingTreatmentAbnormal Liver Function Tests / BMI >27 kg/m21
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Adenocarcinoma Metastatic / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAnemias / Fevers / Lymphadenopathy / Lymphocytosis / Night Sweats / Obese experiencing rapid weight loss / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Plasma Cell Myeloma / Splenomegaly / Thrombocytopenias / Tiredness1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentDiabetes / Hyperlipidemias1
1RecruitingTreatmentHead and Neck Carcinoma1
1RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingTreatmentNeoplasms, Brain1
1RecruitingTreatmentOvarian Epithelial Cancer1
1RecruitingTreatmentPolycystic Ovarian Syndrome1
1RecruitingTreatmentPrimary Brain Tumors / Tumors, Solid1
1RecruitingTreatmentProstate Cancer1
1RecruitingTreatmentType 2 Diabetes Mellitus2
1TerminatedNot AvailableCarcinoma, Colorectal1
1TerminatedNot AvailableGeneralized Anxiety Disorder (GAD)1
1TerminatedNot AvailableType 2 Diabetes Mellitus1
1TerminatedTreatmentMalignant Neoplasm of Colon1
1TerminatedTreatmentType 2 Diabetes Mellitus1
1Unknown StatusTreatmentBMI >30 kg/m2 / Psychotropic Induced Weight Gain / Weight gain therapy1
1Unknown StatusTreatmentDiabetes Mellitus, Non-Insulin-Dependent / Hypertriglyceridemias1
1Unknown StatusTreatmentType 2 Diabetes Mellitus1
1WithdrawnNot AvailableComparative Bioavailability1
1WithdrawnNot AvailableType 2 Diabetes Mellitus1
1WithdrawnTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
1WithdrawnTreatmentOvarian Papillary Serous Carcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer1
1WithdrawnTreatmentStage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
1, 2Active Not RecruitingOtherPre-Diabetic1
1, 2CompletedNot AvailableNonalcoholic Fatty Liver Disease1
1, 2CompletedBasic ScienceType 2 Diabetes Mellitus1
1, 2CompletedDiagnosticType 2 Diabetes Mellitus1
1, 2CompletedPreventionType 2 Diabetes Mellitus1
1, 2CompletedTreatmentHyperlactacidaemia1
1, 2CompletedTreatmentInhibition of physiological lactation therapy / Insulin Resistance / Low Milk Supply / Pre-Diabetic1
1, 2CompletedTreatmentStage IV Pancreatic Cancer1
1, 2CompletedTreatmentType 2 Diabetes Mellitus2
1, 2Not Yet RecruitingTreatmentRecurrent Endometrial Cancer1
1, 2RecruitingBasic SciencePolycystic Ovaries Syndrome1
1, 2RecruitingTreatmentCholangiocarcinomas / Chondrosarcomas / Gliomas1
1, 2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2RecruitingTreatmentHereditary Leiomyomatosis and Renal Cell Cancer / Papillary Renal Cell Carcinoma, Sporadic / Renal Cell Adenocarcinoma1
1, 2RecruitingTreatmentMelanoma2
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2Unknown StatusTreatmentGestational Diabetes Mellitus (GDM)1
2Active Not RecruitingDiagnosticCancer, Breast / Colorectal Cancers1
2Active Not RecruitingPreventionCancer, Breast / Endometrial Cancers / Liver Cancer / Lung Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Melanoma of Skin / Other Solid Malignant Tumors / Prostate Cancer / Rectal Carcinoma / Renal Cancers1
2Active Not RecruitingPreventionErythroplakia / Hyperplasia / Mild Dysplasia / Moderate Dysplasia / Oral Cavity Carcinoma / Oral Leukoplakia / Severe Dysplasia1
2Active Not RecruitingPreventionLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Lung Carcinoma / Bronchioloalveolar Carcinoma / Large Cell Lung Carcinoma / Non-Small Cell Lung Carcinoma (NSCLC) / Recurrent Non-Small Cell Lung Carcinoma / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentCancer, Advanced / EGFR Gene Amplification / Lung Cancer Non-Small Cell Cancer (NSCLC) / Stage IIIB NSCLC / Stage IV NSCLC1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentDiabetes, Gestational / Metformin / Oxidative Stress / Treatments1
2Active Not RecruitingTreatmentDiastolic Dysfunction / Insulin Resistance / Metabolic Syndromes1
2Active Not RecruitingTreatmentEndometrial Cancers1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentOvarian, Fallopian Tube, and Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentProstatic Neoplasms1
2Active Not RecruitingTreatmentRectal Carcinoma1
2Active Not RecruitingTreatmentT2DM With Inadequate Glycemic Control1
2CompletedBasic ScienceCancer, Breast1
2CompletedBasic ScienceDiabetic Foot1
2CompletedBasic SciencePhysical Activity1
2CompletedDiagnosticFibromyalgia / Mitochondrial Diseases / Movement Disorders / Type 2 Diabetes Mellitus1
2CompletedDiagnosticMetabolic Syndromes1
2CompletedPreventionAdenomatous Polyps / BMI >30 kg/m2 / Colorectal Cancers1
2CompletedPreventionAmnestic Mild Cognitive Impairment1
2CompletedPreventionCancer, Breast1
2CompletedPreventionEsophageal Cancers / Esophagus, Barrett1
2CompletedPreventionHypercholesterolaemia / Metabolic Syndromes1
2CompletedPreventionPolycystic Ovaries Syndrome1
2CompletedPreventionType 2 Diabetes Mellitus1
2CompletedPreventionWeight gain therapy1
2CompletedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer1
2CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias / Memory Disturbances1
2CompletedTreatmentBMI >30 kg/m23
2CompletedTreatmentBMI >30 kg/m2 / Hypercholesterolaemia / Hyperglycemias / Hypertensive1
2CompletedTreatmentBMI >30 kg/m2 / Hyperinsulinemia1
2CompletedTreatmentBMI >30 kg/m2 / Hyperinsulinemia / Insulin Resistance1
2CompletedTreatmentBecker's Muscular Dystrophy (BMD)1
2CompletedTreatmentCongestive Heart Failure (CHF) / Type 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetes Mellitus (DM) / Endocrine System Diseases / Nutritional and Metabolic Diseases / Type 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Mellitus (DM) / Glucose Metabolism Disorders / Type 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Mellitus (DM) / Insulin Resistance1
2CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus6
2CompletedTreatmentHepatitis1
2CompletedTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2CompletedTreatmentHypothalamic Obesity1
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
2CompletedTreatmentInsulin Resistance / Metabolic Syndromes / Type 2 Diabetes Mellitus1
2CompletedTreatmentInsulin Resistance / One to five years postmenopausal1
2CompletedTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentNAFLD1
2CompletedTreatmentNon Insulin Dependent Diabetes / Pregnancy1
2CompletedTreatmentPancreatic Adenocarcinoma Advanced or Metastatic1
2CompletedTreatmentPatients With Metabolic Syndrome1
2CompletedTreatmentPeriodontitis1
2CompletedTreatmentPolycystic Ovarian Syndrome1
2CompletedTreatmentPolycystic Ovarian Syndrome / Reproductive Endocrinology1
2CompletedTreatmentPolycystic Ovaries Syndrome2
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRenal Disorder Associated With Type II Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus35
2Enrolling by InvitationTreatmentEndometrial Cancers1
2Enrolling by InvitationTreatmentHyperandrogenism / Polycystic Ovaries Syndrome1
2Not Yet RecruitingTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentInfertility Female1
2Not Yet RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage III Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Not Yet RecruitingTreatmentRenal Insufficiency,Chronic2
2Not Yet RecruitingTreatmentResectable Pancreatic Ductal Adenocarcinoma1
2RecruitingPreventionBMI >30 kg/m2 / Prediabetic State1
2RecruitingPreventionBreast Cancer Prevention1
2RecruitingPreventionCancer, Breast / Tumors, Breast1
2RecruitingPreventionFrailty1
2RecruitingPreventionIntracytoplasmatic Sperm Injection1
2RecruitingPreventionTertiary Prevention in Colon Cancer1
2RecruitingSupportive CareThyroid1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Endometrium1
2RecruitingTreatmentAdenocarcinomas / Carcinoma NOS / Rectal Neoplasms1
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Adenosquamous / Squamous Cell Carcinoma (SCC) / Uterine Cervical Neoplasms1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Colorectal1
2RecruitingTreatmentAge-Related Macular Degeneration (ARMD) / Dry Macular Degeneration / Macular Degeneration, Age-Related1
2RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)2
2RecruitingTreatmentBCT Rate / PCR Rate / Safety1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentBrenner Tumor / Malignant Ascites / Malignant Pleural Effusions / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Ovarian Germ Cell Tumor / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Primary Peritoneal Cavity Cancer1
2RecruitingTreatmentCancer of the Prostate / Prostate Cancer1
2RecruitingTreatmentCancer, Breast2
2RecruitingTreatmentCarcinoma, Breast / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Uterine Corpus Cancer / Uterine Corpus Carcinosarcoma1
2RecruitingTreatmentCarcinoma, Non-squamous Non-small-cell Lung1
2RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Metabolic Syndromes1
2RecruitingTreatmentComplex Endometrial Hyperplasia With Atypia / Grade 1 Endometrial Endometrioid Adenocarcinoma1
2RecruitingTreatmentCoronary Artery Disease / Human Immunodeficiency Virus (HIV)1
2RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Atypical Hyperplasia1
2RecruitingTreatmentEpithelial Ovarian Carcinoma1
2RecruitingTreatmentGlioblastoma Multiforme1
2RecruitingTreatmentHER-2 Positive Breast Cancer1
2RecruitingTreatmentHeart Failure, Systolic1
2RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentHer2-Positive Breast Cancer1
2RecruitingTreatmentHormone Receptor Positive Malignant Neoplasm of Breast1
2RecruitingTreatmentHyperandrogenism / Insulin Resistance / Polycystic Ovaries Syndrome1
2RecruitingTreatmentInsulin Resistance / Type 2 Diabetes Mellitus1
2RecruitingTreatmentLarynx / LIP / Oral Cavity / Pharynx1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2RecruitingTreatmentLung Cancers2
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentNeoplasms, Oropharyngeal / Oral Cavity Neoplasm / Stage I Oral Cavity Squamous Cell Carcinoma / Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 / Stage II Oral Cavity Squamous Cell Carcinoma / Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Squamous Cell Carcinoma / Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v71
2RecruitingTreatmentNonvalvular Atrial Fibrillation1
2RecruitingTreatmentPolycystic Ovarian Syndrome1
2RecruitingTreatmentProstate Cancer5
2RecruitingTreatmentProstate Cancer / Prostate Cancer Recurrent1
2RecruitingTreatmentProstatic Neoplasms1
2RecruitingTreatmentRectal Neoplasm Carcinoma in Situ Adenocarcinoma1
2RecruitingTreatmentRecurrent Prostate Carcinoma / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2RecruitingTreatmentRelapsed Chronic Lymphocytic Leukemia1
2RecruitingTreatmentStage IA Pancreatic Adenocarcinoma / Stage IB Pancreatic Adenocarcinoma / Stage IIA Pancreatic Adenocarcinoma / Stage IIB Pancreatic Adenocarcinoma1
2RecruitingTreatmentType 2 Diabetes Mellitus2
2RecruitingTreatmentWell-differentiated Neuroendocrine Tumors1
2SuspendedTreatmentBMI >30 kg/m2 / Metabolic Syndromes1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentColorectal Cancers / Steatohepatitis1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentMetastatic Non-Small Cell Lung Cancer / Non-small Cell Lung Cancer Stage IIIB/IV / Nonsquamous Nonsmall Cell Neoplasm of Lung1
2TerminatedTreatmentNeoplasms, Colorectal1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentType 2 Diabetes Mellitus9
2TerminatedTreatmentWeight gain therapy1
2Unknown StatusTreatmentBMI >30 kg/m21
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentFamilial Adenomatous Polyposis (FAP)1
2Unknown StatusTreatmentIntrabony Defects in Chronic Periodontitis1
2Unknown StatusTreatmentLocally Advanced Malignant Neoplasm1
2Unknown StatusTreatmentMetabolic Syndromes1
2Unknown StatusTreatmentMetastatic Hormone Refractory Prostate Cancer1
2Unknown StatusTreatmentMetastatic Melanoma (Stage IIIC Non-résécable or no Surgically Curable or Stage IV With Classification AJCC)1
2Unknown StatusTreatmentNonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis1
2Unknown StatusTreatmentPre-Diabetic1
2Unknown StatusTreatmentPreviously Treated Advanced Colorectal Cancer1
2Unknown StatusTreatmentType 2 Diabetes Mellitus1
2WithdrawnNot AvailablePulmonary Arterial Hypertension (PAH)1
2WithdrawnTreatmentEndometrial Cancers1
2WithdrawnTreatmentProstate Cancer3
2, 3CompletedPreventionBMI >30 kg/m2 / Complications, Pregnancy1
2, 3CompletedPreventionDiabetes / Glucose tolerance impaired / Inflammatory Reaction1
2, 3CompletedTreatmentChronic Periodontitis5
2, 3CompletedTreatmentDiabetes1
2, 3CompletedTreatmentGestational Diabetes Mellitus (GDM)1
2, 3CompletedTreatmentPeriodontitis1
2, 3CompletedTreatmentType 2 Diabetes Mellitus5
2, 3CompletedTreatmentMinor burns1
2, 3Not Yet RecruitingTreatmentComplications, Pregnancy / Intrahepatic Cholestases1
2, 3Not Yet RecruitingTreatmentDiabetes Mellitus (DM) / Gastroduodenal Ulcers / Iron Metabolism Disorders / Optic Atrophy / Platelets Dysfunction / Sensorineural Hearing Loss1
2, 3Not Yet RecruitingTreatmentHepatic Steatosis / HIV-1-infection1
2, 3RecruitingHealth Services ResearchPolycystic Ovaries Syndrome1
2, 3RecruitingPreventionDiabetes, Gestational / Polycystic Ovaries Syndrome1
2, 3RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage III Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2, 3RecruitingTreatmentHyperglycemias / Hypermetabolism / Insulin Resistance1
2, 3RecruitingTreatmentProstate Cancer1
2, 3RecruitingTreatmentType 2 Diabetes Mellitus1
2, 3TerminatedTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
2, 3TerminatedTreatmentType 2 Diabetes Mellitus1
2, 3Unknown StatusTreatmentBMI >30 kg/m21
2, 3Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection / Insulin Resistance1
2, 3Unknown StatusTreatmentCoronary Artery Disease / Diabetes / Heart Failure, Unspecified / ST Elevation Myocardial Infarction (STEMI)1
2, 3Unknown StatusTreatmentDiabetes, Gestational / Pregnancy / Type 2 Diabetes Mellitus1
2, 3Unknown StatusTreatmentFatty Liver1
2, 3Unknown StatusTreatmentGlucocorticoid Treatment1
2, 3Unknown StatusTreatmentType 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3Active Not RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentGynecology1
3Active Not RecruitingTreatmentPre-Diabetic / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus7
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionDiabetes / Impaired Glucose Tolerance (IGT)1
3CompletedPreventionPolycystic Ovaries Syndrome2
3CompletedPreventionSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentAbortions spontaneous / Diabetes, Gestational / Infertilities / Polycystic Ovaries Syndrome / Toxemia1
3CompletedTreatmentAnovulatory cycle / Hyperandrogenism / Infertilities / Oligoovulation / Polycystic Ovaries Syndrome1
3CompletedTreatmentAutism Spectrum Conditions/Disorders / BMI >27 kg/m21
3CompletedTreatmentBMI >30 kg/m21
3CompletedTreatmentBMI >30 kg/m2 / Diabetes1
3CompletedTreatmentBMI >30 kg/m2 / Hypogonadism1
3CompletedTreatmentBMI >30 kg/m2 / Insulin Resistance1
3CompletedTreatmentDiabetes3
3CompletedTreatmentDiabetes Mellitus (DM)10
3CompletedTreatmentDiabetes Mellitus (DM) / Dyslipidemias1
3CompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent1
3CompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent / Type 2 Diabetes Mellitus, Non Insulin Dependent1
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus13
3CompletedTreatmentDisorder of Glucose Regulation / Polycystic Ovaries Syndrome1
3CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
3CompletedTreatmentDyslipidemia/Glucose Metabolism Disorder1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3CompletedTreatmentFatty Liver1
3CompletedTreatmentGestational Diabetes Mellitus (GDM)1
3CompletedTreatmentHypercholesterolaemia / Pre-Diabetic / Type 2 Diabetes Mellitus1
3CompletedTreatmentInsulin Sensitivity / Polycystic Ovarian Syndrome1
3CompletedTreatmentMetabolic Syndromes2
3CompletedTreatmentPolycystic Ovaries Syndrome6
3CompletedTreatmentPoor Glycemic Control1
3CompletedTreatmentType 2 Diabetes Mellitus133
3Not Yet RecruitingPreventionMetabolic Syndromes / Prostate Cancer1
3Not Yet RecruitingPreventionNon-DM Stage III Colorectal Cancer1
3Not Yet RecruitingTreatmentDiabetes, Gestational / Insulin Resistance1
3Not Yet RecruitingTreatmentPolycystic Ovarian Syndrome1
3Not Yet RecruitingTreatmentPsoriasis1
3Not Yet RecruitingTreatmentType 2 Diabetes Mellitus2
3RecruitingPreventionAtypical Ductal Breast Hyperplasia / Brca1 Mutation Carrier / Brca2 Mutation Carrier / Ductal Breast Carcinoma In Situ / Lobular Breast Carcinoma In Situ1
3RecruitingPreventionGestational Diabetes Mellitus (GDM)1
3RecruitingPreventionMetabolic Syndromes1
3RecruitingTreatmentAging / Pre-Diabetic1
3RecruitingTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
3RecruitingTreatmentBipolar Disorder (BD)1
3RecruitingTreatmentBrain Tumor Treated With Cranial or Cranial-Spinal Radiation1
3RecruitingTreatmentCancers / Overall Survival / Quality of Life1
3RecruitingTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
3RecruitingTreatmentDiabetes Prevention in Women After GDM Who Are at High-risk1
3RecruitingTreatmentDiabetes, Gestational1
3RecruitingTreatmentDiabetes / Pregnancy1
3RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
3RecruitingTreatmentDyslipidemias / Type 2 Diabetes Mellitus2
3RecruitingTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
3RecruitingTreatmentMigraines1
3RecruitingTreatmentPeripheral Artery Disease (PAD)1
3RecruitingTreatmentPre-Diabetic / Type 2 Diabetes Mellitus1
3RecruitingTreatmentPre-frail Elderly1
3RecruitingTreatmentProstate Cancer1
3RecruitingTreatmentType 2 Diabetes Mellitus11
3TerminatedNot AvailableCoronary and Peripheral Endothelial Dysfunction1
3TerminatedPreventionHepatitis C, Chronic / Hepatocellular,Carcinoma / Liver Cirrhosis1
3TerminatedTreatmentCongestive Heart Failure (CHF) / Type 2 Diabetes Mellitus1
3TerminatedTreatmentDiabetes Mellitus (DM)1
3TerminatedTreatmentDiabetes / Type 2 Diabetes Mellitus3
3TerminatedTreatmentType 2 Diabetes Mellitus10
3Unknown StatusEducational/Counseling/TrainingBMI >30 kg/m21
3Unknown StatusPreventionDiabetes Mellitus (DM)1
3Unknown StatusTreatmentBMI >30 kg/m21
3Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 11
3Unknown StatusTreatmentDiabetes, Gestational / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentPlus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in / Subjects With Type 2 Diabetes Mellitus / The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg1
3Unknown StatusTreatmentType 2 Diabetes Mellitus3
3WithdrawnHealth Services ResearchDiabetes Mellitus (DM)1
3WithdrawnTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
3WithdrawnTreatmentType 2 Diabetes Mellitus1
4Active Not RecruitingBasic ScienceDepressive State / Insulin Resistance / Metabolic Syndromes1
4Active Not RecruitingBasic ScienceDyslipidemias / Type 2 Diabetes Mellitus1
4Active Not RecruitingBasic ScienceHealthy Volunteers1
4Active Not RecruitingPreventionAging1
4Active Not RecruitingPreventionBMI >30 kg/m2 / Gonadal Dysfunction / Insulin Resistance / Type 2 Diabetes Mellitus1
4Active Not RecruitingPreventionMountain Sickness1
4Active Not RecruitingTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Masked Hypertension / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentDiabetes1
4Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
4Active Not RecruitingTreatmentDisorder of Glucose Regulation1
4Active Not RecruitingTreatmentPolycystic Ovaries Syndrome1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus5
4CompletedNot AvailableAmenorrhea1
4CompletedNot AvailableChronic Hepatitis C Infection1
4CompletedNot AvailableDiabetes1
4CompletedNot AvailableDiabetes Mellitus (DM)1
4CompletedNot AvailableOther Conditions That May Be A Focus of Clinical Attention2
4CompletedNot AvailableType 2 Diabetes Mellitus2
4CompletedBasic ScienceDiabetes / Glucose Metabolism Disorders1
4CompletedBasic ScienceType 2 Diabetes Mellitus2
4CompletedHealth Services ResearchMetformin / Organic Cation Transporter 2 / Single Nucleotide Polymorphisms1
4CompletedHealth Services ResearchPharmacogenetics of Metformin1
4CompletedPreventionBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4CompletedPreventionCardiovascular Disease (CVD) / Ischaemic Heart Diseases1
4CompletedPreventionDiabetes, Diabetes Mellitus Type 11
4CompletedPreventionLeft Ventriclar Mass1
4CompletedPreventionMetabolic Complications1
4CompletedPreventionPatients With Glucocorticoid Treatment1
4CompletedPreventionType 2 Diabetes Mellitus1
4CompletedSupportive CareLiver Diseases1
4CompletedTreatmentAging / Inflammatory Reaction / Insulin Resistance / Pre-Diabetic1
4CompletedTreatmentAnovulatory cycle / Infertilities / Polycystic Ovaries Syndrome1
4CompletedTreatmentApoptotic Signal Pathways in Endometrial Hyperplasia1
4CompletedTreatmentArteriosclerosis / Atherosclerosis / Type 2 Diabetes Mellitus1
4CompletedTreatmentAutism Spectrum Conditions/Disorders / Bipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBMI >30 kg/m2 / Polycystic Ovarian Syndrome6
4CompletedTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentBody Weights / Insulin Resistance1
4CompletedTreatmentBody Weights / Polycystic Ovaries Syndrome1
4CompletedTreatmentChronic Hepatitis C Infection1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCongestive Heart Failure (CHF) / Insulin Resistance1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus2
4CompletedTreatmentDepressive State1
4CompletedTreatmentDiabetes2
4CompletedTreatmentDiabetes Ketoacidosis / Hyperglycemias / Ketosis Prone Diabetes1
4CompletedTreatmentDiabetes Mellitus (DM)3
4CompletedTreatmentDiabetes Mellitus (DM) / Endothelial Dysfunction1
4CompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent1
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
4CompletedTreatmentDiabetes, Gestational2
4CompletedTreatmentDiabetes / Hypertensive1
4CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus17
4CompletedTreatmentDyslipidemias1
4CompletedTreatmentEndothelial Function / Ischemia Reperfusion Injury1
4CompletedTreatmentGestational Diabetes Mellitus (GDM)1
4CompletedTreatmentGlucotoxicity / Pancreatic Beta Cell Function / Type 2 Diabetes Mellitus1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4CompletedTreatmentHyperinsulinemia / Insulin Resistance / Pediatric Obesity1
4CompletedTreatmentHypoglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentImpaired Glucose Tolerance (IGT)1
4CompletedTreatmentInfertilities / Polycystic Ovary Syndrome (PCOS)1
4CompletedTreatmentInsufficient Metabolic Control / OAD Treatment / Type 2 Diabetic Patients1
4CompletedTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
4CompletedTreatmentInsulin Sensitivity / Type 2 Diabetes Mellitus1
4CompletedTreatmentIschaemic Heart Diseases / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Type2 Diabetes1
4CompletedTreatmentPCO1
4CompletedTreatmentPediatric Obesity1
4CompletedTreatmentPolycystic Ovarian Syndrome1
4CompletedTreatmentPolycystic Ovaries Syndrome5
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentSchizophrenic Disorders2
4CompletedTreatmentType 2 Diabetes Mellitus56
4CompletedTreatmentWeight gain therapy1
4Enrolling by InvitationPreventionPrediabetic State1
4Enrolling by InvitationTreatmentType 2 Diabetes Mellitus1
4Not Yet RecruitingNot AvailableDiabetes Mellitus (DM) / Hypoglycemic Episodes1
4Not Yet RecruitingBasic ScienceProstate Cancer1
4Not Yet RecruitingPreventionDiabetes1
4Not Yet RecruitingPreventionHypertensive / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentAcanthosis Nigricans1
4Not Yet RecruitingTreatmentAtherosclerosis / Metformin / Prediabetic State1
4Not Yet RecruitingTreatmentBeta Thalassemia Major Anemia1
4Not Yet RecruitingTreatmentCoronary Endothelial Function1
4Not Yet RecruitingTreatmentDiabetes, Gestational / Pregnancy in Diabetes1
4Not Yet RecruitingTreatmentGestational Diabetes Mellitus, Class A21
4Not Yet RecruitingTreatmentInsulin Resistance1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus7
4RecruitingNot AvailableHeart Failure, Systolic1
4RecruitingBasic SciencePolycystic Ovaries Syndrome1
4RecruitingBasic ScienceTolerance1
4RecruitingHealth Services ResearchCoronary Artery Disease / Hypertensive / Mild Cognitive Impairment (MCI) / Obesity, Abdominal1
4RecruitingPreventionGestational Diabetes Mellitus (GDM)1
4RecruitingPreventionInsulin Resistance1
4RecruitingPreventionInsulin Resistance / Prediabetic State1
4RecruitingPreventionPre-Diabetic1
4RecruitingSupportive CareAcromegaly / Cushing's Disease1
4RecruitingTreatmentAtaxia-Telangiectasia1
4RecruitingTreatmentAtherosclerosis / Coronary Artery Disease / Prediabetic State1
4RecruitingTreatmentAtherosclerosis / Diabetes / Restenosis1
4RecruitingTreatmentBMI >27 kg/m2 / Schizoaffective Disorders / Schizophrenic Disorders1
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
4RecruitingTreatmentDiabetes / Type 2 Diabetes Mellitus1
4RecruitingTreatmentEndothelial Function / Type 2 Diabetes Mellitus1
4RecruitingTreatmentGLP-1;Telomere-telomerase System; Par-4 / GLP-1;Metformin;Telomere-telomerase System;Par-41
4RecruitingTreatmentHepatic Encephalopathy / Liver Cirrhosis1
4RecruitingTreatmentHypertensive1
4RecruitingTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Pre-Diabetic1
4RecruitingTreatmentInfertilities1
4RecruitingTreatmentInsulin Resistance / Mild Cognitive Impairment (MCI) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentMetabolic Syndromes / Non-Alcoholic Fatty Liver Disease (NAFLD) / Polycystic Ovaries Syndrome1
4RecruitingTreatmentPeripheral Artery Disease (PAD)1
4RecruitingTreatmentPolycystic Ovarian Syndrome1
4RecruitingTreatmentPolycystic Ovaries Syndrome1
4RecruitingTreatmentSchizophrenic Disorders1
4RecruitingTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
4RecruitingTreatmentType 2 Diabetes Mellitus9
4TerminatedNot AvailableSchizo-Affective Disorder / Schizophrenic Disorders1
4TerminatedPreventionInsulin Sensitivity / Polycystic Ovarian Syndrome / Polycystic Ovaries Syndrome1
4TerminatedTreatmentCoronary Artery Disease1
4TerminatedTreatmentDiabetes / Type 2 Diabetes Mellitus1
4TerminatedTreatmentFatty Liver1
4TerminatedTreatmentInfertilities / Polycystic Ovarian Syndrome / Prognosis for Poor Response1
4TerminatedTreatmentIntermittent Claudication / Peripheral Arterial Disease (PAD)1
4TerminatedTreatmentType 2 Diabetes Mellitus3
4Unknown StatusPreventionBMI >30 kg/m2 / Diabetes, Gestational / Polycystic Ovaries Syndrome1
4Unknown StatusPreventionType 2 Diabetes Mellitus1
4Unknown StatusTreatmentBMI >30 kg/m21
4Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection1
4Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection / Insulin Resistance1
4Unknown StatusTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 11
4Unknown StatusTreatmentDiabetes, Gestational1
4Unknown StatusTreatmentDiabetic Blood Glucose Monitoring / Exercise / Hypoglycemic Agents / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentDrug Induced Weight Gain1
4Unknown StatusTreatmentMetabolic Syndromes1
4Unknown StatusTreatmentPolycystic Ovarian Syndrome1
4Unknown StatusTreatmentPolycystic Ovaries Syndrome2
4Unknown StatusTreatmentPre-Diabetic1
4Unknown StatusTreatmentRecurrent Abortion1
4Unknown StatusTreatmentSevere Hyperglycemia - Blood Glucose Level >300mg/dl / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentType 2 Diabetes Mellitus6
4WithdrawnNot AvailableType 2 Diabetes Mellitus1
4WithdrawnBasic ScienceType 2 Diabetes Mellitus1
4WithdrawnPreventionSchizoaffective Disorders / Schizophrenic Disorders1
4WithdrawnTreatmentBMI >30 kg/m2 / Insulin Resistance1
4WithdrawnTreatmentPolycystic Ovaries Syndrome1
4WithdrawnTreatmentType 2 Diabetes Mellitus3
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Depressive State / Sleep disorders and disturbances / Tiredness1
Not AvailableActive Not RecruitingBasic ScienceBMI >30 kg/m2 / Pre-Diabetic / Type 2 Diabetes Mellitus1
Not AvailableActive Not RecruitingBasic ScienceHyperandrogenism / Polycystic Ovaries Syndrome1
Not AvailableActive Not RecruitingBasic SciencePolycystic Ovaries Syndrome1
Not AvailableActive Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
Not AvailableActive Not RecruitingPreventionBMI >30 kg/m2 / Cancer, Breast1
Not AvailableActive Not RecruitingPreventionCoronary Heart Disease (CHD)1
Not AvailableActive Not RecruitingPreventionNeoplasms, Breast1
Not AvailableActive Not RecruitingTreatmentDiabetes1
Not AvailableActive Not RecruitingTreatmentPolycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailableAcanthosis Nigricans / Hyperinsulinemia / Spectroscopic Analysis1
Not AvailableCompletedNot AvailableCarotid Atherosclerosis / Metabolic Syndromes / Strokes / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDiabetes Mellitus, Type 2 AND Metformin1
Not AvailableCompletedNot AvailableDiabetes / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableEndocrine System Diseases1
Not AvailableCompletedNot AvailableHealthy Volunteers3
Not AvailableCompletedNot AvailablePolycystic Ovarian Syndrome1
Not AvailableCompletedNot AvailablePolycystic Ovary Syndrom / Pregestational Diabetes / Pregnancy1
Not AvailableCompletedNot AvailableProstate Cancer1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus8
Not AvailableCompletedBasic ScienceAcute Lymphoblastic Leukaemias (ALL)1
Not AvailableCompletedBasic ScienceHealthy Adults1
Not AvailableCompletedBasic ScienceHealthy Overweight Obese1
Not AvailableCompletedBasic ScienceTo Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion1
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus7
Not AvailableCompletedDiagnosticBMI >30 kg/m21
Not AvailableCompletedDiagnosticOther Conditions That May Be A Focus of Clinical Attention1
Not AvailableCompletedPreventionAcidosis, Respiratory / Diabetes Mellitus (DM)1
Not AvailableCompletedPreventionPolycystic Ovaries Syndrome / Pregnancy1
Not AvailableCompletedSupportive CareDiabetes1
Not AvailableCompletedTreatmentBMI >30 kg/m22
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Insulin Resistance / Insulin Sensitivity1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Pre-Diabetic1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentDiabetes1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
Not AvailableCompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent1
Not AvailableCompletedTreatmentDiabetes, Gestational1
Not AvailableCompletedTreatmentDiabetes, Gestational / Insulin Resistance1
Not AvailableCompletedTreatmentDiabetes / Heart Failure, Unspecified2
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperinsulinemia / Lipodystrophies1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Metabolic Syndromes1
Not AvailableCompletedTreatmentHyperinsulinism / Polycystic Ovaries Syndrome2
Not AvailableCompletedTreatmentInsulin Resistance1
Not AvailableCompletedTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentInsulin Sensitivity / Metabolic Syndromes / Vascular Function1
Not AvailableCompletedTreatmentMalignant Neoplasm of Thyroid Stage I / Malignant Neoplasm of Thyroid Stage II1
Not AvailableCompletedTreatmentNASH Related Cirrhosis1
Not AvailableCompletedTreatmentNeuromuscular Diseases / Spina Bifida1
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome10
Not AvailableCompletedTreatmentPsoriatic Arthritis1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus7
Not AvailableEnrolling by InvitationNot AvailableDiabetes, Gestational1
Not AvailableNot Yet RecruitingNot AvailableType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Hypertensive / Type 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingTreatmentPolycystic Ovaries Syndrome1
Not AvailableNot Yet RecruitingTreatmentSmall for Gestational Age1
Not AvailableNot Yet RecruitingTreatmentType 2 Diabetes Mellitus2
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceGlucose Metabolism Disorders1
Not AvailableRecruitingOtherEGFR Gene Mutations / Non-Small Cell Adenocarcinoma / Tyrosine kinase mutation1
Not AvailableRecruitingOtherType 2 Diabetes Mellitus1
Not AvailableRecruitingPreventionPrediabetic State / Type 2 Diabetes Mellitus1
Not AvailableRecruitingSupportive CareAging1
Not AvailableRecruitingSupportive CareType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentBMI >30 kg/m2 / Polycystic Ovaries Syndrome1
Not AvailableRecruitingTreatmentComplex Atypical Hyperplasia / Endometrial Cancers1
Not AvailableRecruitingTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentDiabetes2
Not AvailableRecruitingTreatmentDiabetes, Gestational1
Not AvailableRecruitingTreatmentGenetics / Metabolism / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentInsulin Resistance / Major Lung or Abdominal Surgery / Pre-Diabetic1
Not AvailableRecruitingTreatmentMild Graves' Ophthalmopathy1
Not AvailableRecruitingTreatmentPolycystic Ovaries Syndrome3
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentMinor burns1
Not AvailableTerminatedNot AvailableType 2 Diabetes Mellitus1
Not AvailableTerminatedBasic SciencePolycystic Ovaries Syndrome1
Not AvailableTerminatedDiagnosticBMI >30 kg/m2 / Diabetes / Pre-Diabetic1
Not AvailableTerminatedDiagnosticType 2 Diabetes Mellitus1
Not AvailableTerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Diabetes Mellitus (DM) / Hyperglycemias / Insulin Resistance1
Not AvailableTerminatedTreatmentBMI >30 kg/m2 / Schizophrenic Disorders1
Not AvailableTerminatedTreatmentCancer, Breast1
Not AvailableTerminatedTreatmentMetabolic Syndromes1
Not AvailableTerminatedTreatmentPremature Pubarche1
Not AvailableTerminatedTreatmentProstate Cancer1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusNot AvailableCancer, Breast1
Not AvailableUnknown StatusNot AvailableNutritional and Metabolic Diseases1
Not AvailableUnknown StatusNot AvailableType 2 Diabetes Mellitus2
Not AvailableUnknown StatusBasic SciencePolycystic Ovaries Syndrome1
Not AvailableUnknown StatusPreventionPre-Diabetic / Pre-Hypertension1
Not AvailableUnknown StatusTreatmentBMI >30 kg/m2 / Metabolic Syndromes / Schizophrenic Disorders1
Not AvailableUnknown StatusTreatmentCardiovascular Disease (CVD)1
Not AvailableUnknown StatusTreatmentComplications, Pregnancy1
Not AvailableUnknown StatusTreatmentDiabetes, Gestational / Pregnancy / Type 2 Diabetes Mellitus1
Not AvailableUnknown StatusTreatmentEndothelial Dysfunction / Polycystic Ovaries Syndrome1
Not AvailableUnknown StatusTreatmentLiver Diseases1
Not AvailableUnknown StatusTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
Not AvailableUnknown StatusTreatmentPolycystic Ovaries Syndrome5
Not AvailableUnknown StatusTreatmentType 2 Diabetes Mellitus4
Not AvailableUnknown StatusTreatmentType 2 Diabetes Mellitus ;Obesity,High Triglycerides;TCM1
Not AvailableWithdrawnNot AvailableDiabetes Mellitus (DM)1
Not AvailableWithdrawnNot AvailableType 2 Diabetes Mellitus1
Not AvailableWithdrawnPreventionAmenorrhea / Weight gain therapy1
Not AvailableWithdrawnPreventionGestational Diabetes Mellitus (GDM)1
Not AvailableWithdrawnTreatmentBMI >30 kg/m2 / Hypercholesterolaemia / Hypertensive / Insulin Resistance / Metabolic Syndromes1
Not AvailableWithdrawnTreatmentColorectum1
Not AvailableWithdrawnTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Ranbaxy pharmaceuticals inc
  • Andrx labs llc
  • Bristol myers squibb co
  • Depomed inc
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Barr laboratories inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Neurosci inc
  • Nostrum pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Torrent pharma inc
  • Torrent pharmaceuticals ltd
  • Watson laboratories inc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Bristol myers squibb co pharmaceutical research institute
  • Alphapharm party ltd
  • Alvogen inc
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories inc
  • Genpharm inc
  • Glenmark generics ltd
  • Granules india ltd
  • Indicus pharma llc
  • Ipca laboratories ltd
  • Mutual pharmacal co
  • Provident pharmaceutical inc
  • Watson laboratories
Packagers
Dosage forms
FormRouteStrength
Kit
Kit
Tablet, extended releaseOral1000 mg/1
TabletOral1000 mg
TabletOral850 mg
Tablet, extended releaseOral500 mg/1
Tablet, extended releaseOral750 mg/1
Tablet, extended releaseOral1000 mg
Tablet, extended releaseOral500 mg
Tablet, film coated, extended releaseOral1000 mg/1
Tablet, film coated, extended releaseOral500 mg/1
TabletOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
TabletOral1000 mg/1
TabletOral500 mg/1
TabletOral850 mg/1
Tablet, film coatedOral1000 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral850 mg/1
TabletOral750 mg/1
Tablet, film coatedOral750 mg/1
Tablet, film coatedOral
SolutionOral500 mg/5mL
TabletOral500 mg
Prices
Unit descriptionCostUnit
Fortamet er 1000 mg tablet6.93USD tablet
Fortamet 1000 mg 24 Hour tablet6.01USD tablet
Fortamet 500 mg 24 Hour tablet2.55USD tablet
Fortamet er 500 mg tablet2.48USD tablet
Glucophage 1000 mg tablet2.33USD tablet
Metformin hcl crystals2.14USD g
Glucophage 850 mg tablet1.94USD tablet
Glucophage XR 750 mg 24 Hour tablet1.8USD tablet
Glucophage xr 750 mg tablet1.71USD tablet
Metformin hcl 1000 mg tablet1.48USD tablet
MetFORMIN HCl 750 mg 24 Hour tablet1.25USD tablet
Metformin hcl 850 mg tablet1.22USD tablet
Glucophage XR 500 mg 24 Hour tablet1.17USD tablet
Glucophage 500 mg tablet1.14USD tablet
Glucophage xr 500 mg tablet1.14USD tablet
Glucophage xr 500 mg tablet sa1.11USD tablet
MetFORMIN HCl 500 mg 24 Hour tablet0.75USD tablet
Metformin hcl 500 mg tablet0.72USD tablet
Glucophage 850 mg Tablet0.38USD tablet
Glucophage 500 mg Tablet0.3USD tablet
Riomet 500 mg/5 ml solution0.27USD ml
Riomet 500 mg/5ml Solution0.27USD ml
Apo-Metformin 850 mg Tablet0.21USD tablet
Co Metformin 850 mg Tablet0.21USD tablet
Mylan-Metformin 850 mg Tablet0.21USD tablet
Novo-Metformin 850 mg Tablet0.21USD tablet
Nu-Metformin 850 mg Tablet0.21USD tablet
Pms-Metformin 850 mg Tablet0.21USD tablet
Ratio-Metformin Hydrochloride 850 mg Tablet0.21USD tablet
Sandoz Metformin Fc 850 mg Tablet0.21USD tablet
Pms-Metformin 500 mg Tablet0.13USD tablet
Ran-Metformin 500 mg Tablet0.13USD tablet
Ratio-Metformin Hydrochloride 500 mg Tablet0.13USD tablet
Sandoz Metformin Fc 500 mg Tablet0.13USD tablet
Zym-Metformin 500 mg Tablet0.13USD tablet
Apo-Metformin 500 mg Tablet0.13USD tablet
Co Metformin 500 mg Tablet0.13USD tablet
Mylan-Metformin 500 mg Tablet0.13USD tablet
Novo-Metformin 500 mg Tablet0.13USD tablet
Nu-Metformin 500 mg Tablet0.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2476496No2009-12-152023-02-21Canada
CA2412671No2006-10-032021-02-26Canada
US7326708No2006-04-112026-04-11Us
US7407955No2003-08-122023-08-12Us
US6150383No1996-06-192016-06-19Us
US6211205No1996-06-192016-06-19Us
US6303640No1996-08-092016-08-09Us
US6329404No1996-06-192016-06-19Us
US6699871No2002-07-262022-07-26Us
US7125873No2002-07-262022-07-26Us
US5965584No1996-06-192016-06-19Us
US6166042No1996-06-192016-06-19Us
US6166043No1996-06-192016-06-19Us
US6172090No1996-06-192016-06-19Us
US6790459No2001-03-172021-03-17Us
US7919116No1998-03-202018-03-20Us
US8475841No1998-03-202018-03-20Us
US6099859No1998-03-202018-03-20Us
US6866866No2001-03-172021-03-17Us
US7785627No2006-07-312026-07-31Us
US7959946No2006-07-312026-07-31Us
US8470368No2003-09-192023-09-19Us
US8668931No2003-09-192023-09-19Us
US9060941No2003-09-192023-09-19Us
US6495162No1998-03-202018-03-20Us
US8414921No2008-07-212028-07-21Us
US6288095Yes1997-08-112017-08-11Us
US7358366Yes2000-10-192020-10-19Us
US6150384No1996-06-192016-06-19Us
US6303146Yes2000-01-142020-01-14Us
US6660300No1998-03-192018-03-19Us
US6475521No1998-03-192018-03-19Us
US8236345No2002-10-072022-10-07Us
US6890957No2003-09-142023-09-14Us
US6340475No1996-09-192016-09-19Us
US6635280No1996-09-192016-09-19Us
US6488962No2000-06-202020-06-20Us
US7780987No2005-03-232025-03-23Us
US8323692No2005-03-232025-03-23Us
US6723340No2001-10-252021-10-25Us
US9101660No2007-01-222027-01-22Us
US6303661No1997-04-242017-04-24Us
US6890898No1999-02-022019-02-02Us
US7078381No1999-02-022019-02-02Us
US7459428No1999-02-022019-02-02Us
US7807689No2008-06-272028-06-27Us
US8173663No2005-03-152025-03-15Us
US8288539No2005-03-152025-03-15Us
USRE44186No2003-07-312023-07-31Us
US8119648No2003-08-122023-08-12Us
US8178541No2003-08-122023-08-12Us
US8846695No2010-06-042030-06-04Us
US9173859No2007-05-042027-05-04Us
US8673927No2007-05-042027-05-04Us
US8883805No2005-11-262025-11-26Us
US9155705No2010-05-212030-05-21Us
US8628799No2005-07-132025-07-13Us
US8900638No2009-05-242029-05-24Us
US8222219No2004-07-302024-07-30Us
US8513202No2007-12-032027-12-03Us
US7943582No2009-02-262029-02-26Us
US8785403No2004-07-302024-07-30Us
US7943788No2007-07-142027-07-14Us
US8685934No2010-05-262030-05-26Us
US8501698No2007-06-202027-06-20Us
US6414126No2000-10-042020-10-04Us
US6515117No2000-10-042020-10-04Us
US6936590No2000-10-042020-10-04Us
US9198925No2000-10-042020-10-04Us
US7919598No2009-12-162029-12-16Us
US7713938No2007-04-152027-04-15Us
US7579449No2005-11-052025-11-05Us
US9320714No2009-02-032029-02-03Us
US9415016No2009-04-022029-04-02Us
US9339472No2005-07-132025-07-13Us
US9555001No2013-03-062033-03-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)223-226 °CNot Available
water solubilityFreely soluble as HCl saltNot Available
logP-0.5Not Available
pKa12.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.38 mg/mLALOGPS
logP-1.8ALOGPS
logP-0.92ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)12.33ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area88.99 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity56.64 m3·mol-1ChemAxon
Polarizability13.43 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.5868
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.6643
P-glycoprotein inhibitor INon-inhibitor0.9613
P-glycoprotein inhibitor IINon-inhibitor0.8892
Renal organic cation transporterNon-inhibitor0.7518
CYP450 2C9 substrateNon-substrate0.7929
CYP450 2D6 substrateNon-substrate0.7325
CYP450 3A4 substrateNon-substrate0.6906
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9159
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.913
CYP450 3A4 inhibitorNon-inhibitor0.9506
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9763
Ames testNon AMES toxic0.7367
CarcinogenicityNon-carcinogens0.6691
BiodegradationNot ready biodegradable0.938
Rat acute toxicity1.7407 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9807
hERG inhibition (predictor II)Non-inhibitor0.9274
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-001i-0900000000-9046e2aa0408a0396007
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-01qi-9700000000-a6b98d87cc840a082179
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-00dr-9000000000-8e80f301bad045540477
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-001i-0900000000-bd8aed328c944acd1270
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-03l9-9300000000-3d585674ffe84238e5bf
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-00di-9000000000-ee68820579ebe4d31082
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-00di-9000000000-4312e7e5e1b0dd9ef936
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-00di-9000000000-053d63fe09a95fc1d544
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0229-9100000000-7fe999a9d1aaae3bbe53
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-c235cd5d0dda3f3c28d9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-0fa445716bfc24131a75
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-3900000000-dee37da326e6f0b2c56a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-45bd1f8c6d2dc4f38944
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-1900000000-38f3dedb5c19900cdefb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-7900000000-bf5d1092aa372c303d61
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03l9-9300000000-06a99f0dff4b41a23cfa
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-022i-9100000000-811c9e7cf8b30b27c0f2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-9000000000-d34b9b3ab9eb78317eba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-4d53ac0f7dfaf860e784
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-1900000000-4b3dd439b62cfa2341b0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-6900000000-c595d8e83955ee66df73
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03l9-9300000000-1feb1004b70a7c1f7679
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-022i-9100000000-588dd4672e983d25189b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-9000000000-fdc1342fbdd0301080c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-3900000000-f3959910a3d1ce1d1379
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03e9-9400000000-8fb5bd0de13e43cd9f9d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0229-9000000000-c5ee1ab43a4feb174be3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fu-9000000000-47265a863ca46a89f907
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-bd8aed328c944acd1270
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03l9-9300000000-3731f8e1b241c81f11e7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9000000000-ee68820579ebe4d31082
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9000000000-4312e7e5e1b0dd9ef936
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-9000000000-a112b8bb95bd75e1ce02
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-008i-8900000000-043e7607037d942cc570
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dr-9100000000-def4e48e0953ae8f3442
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-9100000000-2d692211680a93c2054e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-9100000000-49305dce40b0f4453fc4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03e9-9400000000-f625291fda51aa198464
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as biguanides. These are organic compounds containing two N-linked guanidines.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Guanidines
Direct Parent
Biguanides
Alternative Parents
Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Imines / Hydrocarbon derivatives
Substituents
Biguanide / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organopnictogen compound / Hydrocarbon derivative / Imine / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
guanidines (CHEBI:6801)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Protein kinase activity
Specific Function
Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellul...
Gene Name
PRKAB1
Uniprot ID
Q9Y478
Uniprot Name
5'-AMP-activated protein kinase subunit beta-1
Molecular Weight
30382.085 Da
References
  1. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR: Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem. 2003 Oct 10;278(41):39422-7. Epub 2003 Jul 29. [PubMed:12890675]
  2. Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003 Dec;144(12):5179-83. Epub 2003 Sep 4. [PubMed:12960015]
  3. Ruderman NB, Saha AK, Kraegen EW: Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology. 2003 Dec;144(12):5166-71. Epub 2003 Sep 18. [PubMed:14500570]
  4. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, Fontaine E, Wiernsperger NF: Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab. 2003 Sep;29(4 Pt 2):6S88-94. [PubMed:14502105]
  5. Leclerc I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbutt GS, Rajotte RV, Smith R, Rutter GA: Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E1023-31. Epub 2004 Feb 10. [PubMed:14871885]
  6. Vucicevic L, Misirkic M, Janjetovic K, Harhaji-Trajkovic L, Prica M, Stevanovic D, Isenovic E, Sudar E, Sumarac-Dumanovic M, Micic D, Trajkovic V: AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93. doi: 10.1016/j.bcp.2009.03.005. Epub 2009 Mar 14. [PubMed:19428322]
  7. Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007 Feb 16;100(3):328-41. [PubMed:17307971]
  8. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ: Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002 Jul;51(7):2074-81. [PubMed:12086935]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM: Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res. 2002 Aug;19(8):1244-7. [PubMed:12240953]
  2. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709]
  3. Zolk O: Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther. 2009 Dec;86(6):595-8. doi: 10.1038/clpt.2009.144. [PubMed:19915604]
  4. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H, Brockmoller J: The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17. [PubMed:19536068]
  5. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergstrom CA, Artursson P: Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42. doi: 10.1021/jm8003152. Epub 2008 Sep 13. [PubMed:18788725]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM: Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res. 2002 Aug;19(8):1244-7. [PubMed:12240953]
  2. Zolk O: Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther. 2009 Dec;86(6):595-8. doi: 10.1038/clpt.2009.144. [PubMed:19915604]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  4. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K: Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86. [PubMed:16272756]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M: Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60. Epub 2005 Nov 2. [PubMed:16263091]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB: Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6. [PubMed:20053795]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Nucleoside transmembrane transporter activity
Specific Function
Functions as a polyspecific organic cation transporter, efficiently transporting many organic cations such as monoamine neurotransmitters 1-methyl-4-phenylpyridinium and biogenic amines including s...
Gene Name
SLC29A4
Uniprot ID
Q7RTT9
Uniprot Name
Equilibrative nucleoside transporter 4
Molecular Weight
58058.005 Da
References
  1. Zhou M, Xia L, Wang J: Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007 Oct;35(10):1956-62. Epub 2007 Jun 28. [PubMed:17600084]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13